ClinicalTrials.gg
RecruitingNCT06884748PREVENTUpdated Nov 2, 2026

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

An Early Phase 1 interventional study of Ursodiol 500 MG in Clostridioides Difficile Infection, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Medical College of Wisconsin · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 2, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.

Planned enrollment
64th of 102
30 · median 57
Started
2026
with 5 others
Phase 1
18 of 121
5 open now
Primary completion
2028-05
later than 13 of 18 live
Registered
114th of 121
by date
Lead sponsor
4 of 121
Medical College of Wisconsin

Among the 121 studies in Clostridium Infections with a site in United States, this one is the 64th largest by planned enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 13 of the 18 other live ones, and was the 114th registered.

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

Browse Clostridium Infections studies →

Open to participants now

16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Clostridium Infections with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C. diff colitis is a serious infection that can return after treatment, and researchers want to see if UDCA can reduce this risk.

This study aims to answer three main questions. First, can UDCA help prevent C. diff from returning after standard treatment? Second, does adding UDCA to treatment lower the need for repeated antibiotic use? Third, is UDCA safe and well-tolerated for people with C. diff?

Participants in the study will be adults diagnosed with C. diff colitis who have risk factors for recurrence. Each participant will receive standard antibiotic treatment, which may include Vancomycin, Fidaxomicin, or Metronidazole. In addition to their antibiotic therapy, participants will take UDCA at a dose of 500 mg three times a day for up to eight weeks. If a participant's stool test shows they are C. diff negative at four weeks, they will stop taking UDCA early.

Researchers will monitor participants throughout the study. Stool samples will be tested at the beginning, after four weeks, and at the end of the study. If a participant develops diarrhea, a stool test will check for C. diff. If C. diff is negative, the UDCA dose will be reduced. Weekly phone calls will be made to check for side effects and ensure participants are following the treatment plan.

C. diff colitis is a common and serious infection, with up to 46 percent of high-risk patients experiencing recurrence. Current treatments rely on antibiotics, which can disrupt gut bacteria and increase the risk of reinfection. UDCA is a naturally occurring bile acid that may help prevent C. diff from growing, reducing the need for repeated antibiotic treatment. If successful, this study could introduce a new way to prevent C. diff from coming back, helping patients recover more effectively while reducing antibiotic use.

Eligible participants must be at least 18 years old, have a positive C. diff test, and be receiving standard antibiotic treatment for C. diff. People who have severe or life-threatening C. diff colitis, a life expectancy of less than six months, serious liver disease, or are pregnant or breastfeeding will not be eligible to participate.

UDCA is FDA-approved and has been used safely for decades in liver diseases and gallstone treatment. Some people may experience mild side effects, such as diarrhea, nausea, or stomach discomfort. Participants will be closely monitored for safety throughout the study.

This trial will take place within the Froedtert and Medical College of Wisconsin healthcare system in Milwaukee, Wisconsin.

Read the detailed description

Prevention of Recurrence of Clostridioides Difficile Colitis with

Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

Paraj D. Patel M.D, Daniel J. Stein, M.D, Helmut V. Ammon, MD

This proposal describes the use of UDCA as an adjunct to standard treatment of C. difficile (C. diff) colitis for the prevention of recurrence of the disease.

The Problem: C. diff colitis is a serious burden on the healthcare system. In 2011 there were close to 500,000 cases of and 29,000 deaths from C. diff. colitis reported in the US at an annual cost of 58 billion dollars [1, 2] Treatment consists of Vancomycin or Fidaxomicin [3]. The recurrence rate is between 7% and 20% within 2 months [1, 4]. The risk of recurrence increases with each episode and various risk factors to up to 46% in the presence of more than 3 risk factors[5, 6]. Current efforts to deal with this problem include prolonged treatment with antibiotics, fecal microbiota transplants, probiotics, and monoclonal antibodies [7] .

Recurrent C. diff. infection is associated with is a loss of diversity in the fecal microbiome and the consequent loss of the ability to deconjugate bile acids [6, 8]. Stool from patients with recurrent C. diff. colitis requiring fecal transplant contains mainly taurocholate and no secondary bile acids [9]. In in vitro studies taurocholate facilitates the germination of C. difficile spores and the growth of the vegetative form [10]. For this reason, taurocholate is used in the growth medium for the culture of C. diff [9]. Treatment of recurrent C. diff. colitis with fecal transplants is directed at restoration of the diversity of the fecal microbiome and restoration of a normal fecal bile acid profile [3, 11, 12]

The Solution:

UDCA, a secondary bile acid derived from chenodeoxycholic acid in the human colon, inhibits the germination of C. diff in vitro at a and its growth of the vegetative form in concentration as low as 0.5 mmol/L [13, 14]

This observation prompted the use of UDCA (1200 mg/day) for the successful treatment of a patient with an ileo-anal pouch with recurrent intractable C. difficile pouchitis [14]. A subsequent uncontrolled case series reported the successful control of recurrent C. difficile colitis in 14 out of 16 patients with UDCA (600 - 900 mg/day) given for 29 - 235 days[15].

Three different studies using different experimental designs indicate that UDCA is poorly absorbed and that adequate doses of UDCA could deliver adequate colonic concentrations to prevent germination and inhibit growth of C. difficile [16-18]

Experimental Design and Calculation of Sample size

We assume that a higher dose of UDCA (1500 mg/day) could improve the results observed by Webb et al [15]. Assuming a fecal weight of 400g/day (diarrhea) with the corresponding volume of distribution of 400 ml the patients in the study by Webb et al [14] would have had a fecal concentration of UDCA of 1.8 mmol/L, based on the absorption rates observed by Walker et al [17]. The dose of UDCA in our proposal (1500 mg/day) would result in a fecal UDCA concentration of 7 mmol/L, well above the 0.5 mmol/l inhibiting vegetative growth of C. diff in vitro [11,12]

For the exploratory study we propose to use a single arm, open label design with historical controls. Use of historical controls is justified if the study population is small, as in our single center study, and the outcome in question is dichotomous [19].

As historical controls we will use the placebo group of the treatment trial of the use of Bezlutoxumab for the prevention of the recurrence of C. difficile colitis [7]. Using patients with ≥1 risk factors we would get a sample size in the control group of n = 468 with a recurrence rate of 37.2 %. Since the outcome is dichotomous (Recurrence yes/no) we used the ClinCalc sample size calculator to determine the necessary Number to Treat. Assuming a 12.5% recurrence rate for a minimal response [13] the necessary Number to Treat is 25 (plus 2 to account for drop-outs) (for Type I/II error: Alpha 0.05; Beta 0.2; Power 0.8). In the study the proposed dose of UDCA will be 1500 mg/day (approximately 20 mg/kg/day) in divided doses. The dose was chosen to get adequate colonic concentrations of UDCA while reducing the risk of drug induced diarrhea [18-22]. The duration of treatment will be 60 days, the time interval for most recurrences to occur [1, 3].

Safety:

UDCA has been widely used for the dissolution of gallstones prior to the advent of laparoscopic cholecystectomy [20] and is currently the FDA approved treatment of choice for Primary Biliary Cholangitis (PBC)[21]. It is the treatment of choice for cholestasis of pregnancy (ICP)[22], and for the prevention of gallstone formation after gastric bypass surgery [23]. It is also being used for treatment of primary sclerosing cholangitis (PSC) [24], liver disease due to cystic fibrosis [25], and for the prevention of hepatic complications in allogenic stem cell transplantation [26].

The safety of the administration of UDCA as high as 30 mg/kg/24 hours (50 % higher than in our proposal) is well established. Nine studies report the use of UCDA 28-35 mg/kg/day for weeks to 3 years in treatment trials in 378 patients, 74 with PBC [27, 28], 115 with PSC [29-31], 169 with nonalcoholic steato-hepatitis (NASH)[32-34], and 20 with ICP [22]

Only one study of patients with NASH reports significant side effects (diarrhea in 38.7% vs. 17.2 % in the placebo group (p\<0.01) and abdominal discomfort in 25.8% vs. 10.9% (p\<0.04) [34]. One study of 12 patients with NASH reported diarrhea in 2 and fatigue and pruritus in 1 [33]. One study of 54 patients with PBC reports 2 cases with diarrhea, 2 with nausea and vomiting, 1 with thrombocytopenia, and 1 with a skin rash [27]. In a study of patients with NASH 11/95 patients receiving UDCA developed diarrhea vs 1/91 in the placebo group [32]. In a study of 10 patients with PSC receiving high dose UDCA one developed cholangitis, 1 underwent cholecystectomy and 1 reported loss of libido [29]. The largest study of the use of high dose UDCA in PSC was terminated after three years because of a higher incidence of adverse effect on outcomes of the liver disease in comparison to the placebo group [31]. A retrospective analysis of this study also found a higher incidence of neoplastic changes in the colon in patients with chronic ulcerative colitis in comparison with the control group after 2 years of therapy [35]. Taking all studies together 17.9 % of patients receiving high dose UDCA developed diarrhea. A systematic review of the literature found no serious side effects with the use of UDCA [36]

We therefore feel justified to test the ability of UDCA administered at a dose of 1500 mg/day in divided doses (approximately 20 mg/kg/day) to prevent the recurrence of C. difficile colitis in a pilot program, enrolling consecutive patients and comparing the outcome to historical controls.

PROTOCOL

.

Eligible patients: C. diff. toxin +ve patients > 18 years with one or more risk factors for recurrence [6,7] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.

Exclusion criteria: Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.

Treatment: Standard treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID. UDCA to be started while patient is on antibiotics for C. diff. for 8 weeks (unless C. diff negative by 4 weeks).

Follow-up for 6 moths.

Endpoint: Relapse yes/no

Monitoring:

Check stool for C. diff (PCR/toxin) at entry, at 4 weeks, and at completion. If C. diff negative by 4 weeks stop treatment. If patient reports diarrhea, check stool for C. diff. toxin. If negative, reduce UDCA by 25%.

Weekly telephone call to patient to check on side effects and encourage compliance

Ribotyping of C. diff at entry

Recruitment:

Potential patient pool: Patients within the Froedtert/MCW health care

system in the greater Milwaukee area

Lab issues daily list of C. diff positive patients

Obtain permission from PCP to contact patient,

Screen for exclusions,

Obtain informed consent,

Enroll patient,

Budget:

Number of patients: 27

Medication: Ursodeoxycholic acid 500 mg capsules: (n=4,860)

Pharmacy quote: $ 96.78/100 $ 4,704.--

Cost of stool test for C. difficile at 4 and 8 weeks

Cost for profiling of C. diff strains (ribotyping)

References

  1. Lessa, F.C., et al., Burden of Clostridium difficile infection in the United States. N Engl J Med, 2015. 372(9): p. 825-34.
  2. Depestel, D.D. and D.M. Aronoff, Epidemiology of Clostridium difficile infection. J Pharm Pract, 2013. 26(5): p. 464-75.
  3. Surowiec, D., et al., Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother, 2006. 40(12): p. 2155-63.
  4. Liu, C., et al., Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective. Antibiotics (Basel), 2023. 12(7).
  5. Brown, K.A., et al., Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother, 2013. 57(5): p. 2326-32.
  6. Chang, J.Y., et al., Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis, 2008. 197(3): p. 435-8.
  7. Gerding, D.N., et al., Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis, 2018. 67(5): p. 649-656.
  8. Hofmann, A.F. and L.R. Hagey, Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res, 2014. 55(8): p. 1553-95.
  9. Weingarden, A.R., et al., Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PLoS One, 2016. 11(1): p. e0147210.
  10. Abt, M.C., P.T. McKenney, and E.G. Pamer, Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol, 2016. 14(10): p. 609-20.
  11. Papazyan, R., et al., Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection. Microorganisms, 2023. 11(1).
  12. Weingarden, A.R., et al., Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol, 2014. 306(4): p. G310-9.
  13. Sorg, J.A. and A.L. Sonenshein, Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol, 2010. 192(19): p. 4983-90.
  14. Weingarden, A.R., et al., Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. J Clin Gastroenterol, 2016. 50(8): p. 624-30.
  15. Webb, B.J., et al., Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection. Clin Infect Dis, 2019. 68(3): p. 498-500.
  16. Stiehl, A., R. Raedsch, and G. Rudolph, Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology, 1988. 94(5 Pt 1): p. 1201-6.
  17. Walker, S., et al., Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology, 1992. 102(3): p. 810-5.
  18. Invernizzi, P., et al., Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology, 1999. 29(2): p. 320-7.
  19. Evans, S.R., Clinical trial structures. J Exp Stroke Transl Med, 2010. 3(1): p. 8-18.
  20. Bachrach, W.H. and A.F. Hofmann, Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I. Dig Dis Sci, 1982. 27(8): p. 737-61.
  21. Lindor, K.D., et al., Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019. 69(1): p. 394-419.
  22. Mazzella, G., et al., Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology, 2001. 33(3): p. 504-8.
  23. Haal, S., et al., Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol, 2021. 6(12): p. 993-1001.
  24. Lindor, K.D., et al., ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol, 2015. 110(5): p. 646-59; quiz 660.
  25. Cheng, K., D. Ashby, and R.L. Smyth, Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev, 2014(12): p. CD000222.
  26. Ruutu, T., et al., Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant, 2014. 20(1): p. 135-8.
  27. Angulo, P., et al., Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol, 1999. 30(5): p. 830-5.
  28. Roda, E., et al., Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis, 2002. 34(7): p. 523-7.
  29. Cullen, S.N., et al., High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol, 2008. 48(5): p. 792-800.
  30. Harnois, D.M., et al., High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol, 2001. 96(5): p. 1558-62.
  31. Lindor, K.D., et al., High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009. 50(3): p. 808-14.
  32. Leuschner, U.F., et al., High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010. 52(2): p. 472-9.
  33. Adams, L.A., et al., A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int, 2010. 4(3): p. 628-33.
  34. Ratziu, V., et al., A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol, 2011. 54(5): p. 1011-9.
  35. Eaton, J.E., et al., High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol, 2011. 106(9): p. 1638-45.
  36. Hempfling, W., K. Dilger, and U. Beuers, Systematic review: ursodeoxycholic acid--adverse effects and drug interactions. Aliment Pharmacol Ther, 2003. 18(10): p. 963-72.
03

Conditions studied

  • Clostridioides Difficile Infection

Keywords

  • Clostridioides difficile infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible patients: C. diff. toxin +ve patients > 18 years with one or more risk factors for recurrence [6,7] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.

Exclusion criteria

Exclusion Criteria:

  • \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    UDCA Arm

    Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.

    Drug: Ursodiol 500 MG

Interventions

  • DrugUrsodeoxycholic AcidStudies of Ursodeoxycholic AcidUrsodeoxycholic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.

06

What researchers measure

Primary outcomes

  1. Lack of recurrent C. difficile recurrence

    Absence of recurrent C. difficile recurrence based on symptoms and standard of care testing at 3 months and repeat stool testing at 8 weeks.

    Time frame: 8 weeks and 3 months

07

Study locations

1 of 1 sites recruiting
  • Daniel Stein
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Daniel Stein, MD · Contactdstein@mcw.edu · 4149556858
    • Helmut Ammon, MD · Contacthammon@mcw.edu · 4149556858
    • Paraj Patel, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De Identified participant information and results

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2028, 22 months after the start.

Of 15 phase 1 interventional studies under Clostridium Infections, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 22 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start May 2026 → Jun 2026 and primary completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 19, 2025
StartActual
Jun 30, 2026was May 2026
Primary completionEst.
May 1, 2028was May 2027
CompletionEst.
May 1, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
Daniel Stein is now Recruiting
Nov 2, 2026
Start date
May 1, 2026→Jun 30, 2026 (actual)
Nov 2, 2026
Primary completion
May 1, 2027→May 1, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    Daniel Stein is now Recruiting
    Start date May 1, 2026→Jun 30, 2026 (now actual)
    Primary completion May 1, 2027→May 1, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06884748
Responsible party
Daniel Stein (Professor, Medical College of Wisconsin) — Principal investigator
First posted
Mar 19, 2025
Start date
Jun 30, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Daniel Stein, MD
Contact
dstein@mcw.edu
14149556858
Helmut Ammon, MD
Contact
hammon@mcw.edu
4149556858

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ursodeoxycholic Acid

Start the discussion